These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

166 related items for PubMed ID: 11453341

  • 1. Normocholesterolaemic dysslipidaemia: is there a role for fibrates?
    Hamilton-Craig I.
    Med J Aust; 2001 Jun 04; 174(11):610; author reply 611. PubMed ID: 11453341
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. A case for lipid-lowering?
    Durrington P.
    Diabet Med; 2000 Sep 04; 17 Suppl 2():4-5. PubMed ID: 11048824
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. [Drug combination therapies for patients with hyperlipidemia and its significance].
    Onuma T, Kawamori R.
    Nihon Rinsho; 2001 Mar 04; 59 Suppl 3():566-71. PubMed ID: 11347133
    [No Abstract] [Full Text] [Related]

  • 8. Comparison in patients with type 2 diabetes of fibric acid versus hepatic hydroxymethyl glutaryl-coenzyme a reductase inhibitor treatment of combined dyslipidemia.
    McLaughlin T, Abbasi F, Lamendola C, Leary E, Reaven GM.
    Metabolism; 2002 Oct 04; 51(10):1355-9. PubMed ID: 12370858
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. [Update: clinical lipidology].
    Parhofer KG.
    MMW Fortschr Med; 2013 Jul 25; 155(13):49-52; quiz 53-4. PubMed ID: 23964509
    [No Abstract] [Full Text] [Related]

  • 13. Efficacy and safety of a combination of fluvastatin and bezafibrate in patients with mixed hyperlipidaemia (FACT study).
    Pauciullo P, Borgnino C, Paoletti R, Mariani M, Mancini M.
    Atherosclerosis; 2000 Jun 25; 150(2):429-36. PubMed ID: 10856536
    [Abstract] [Full Text] [Related]

  • 14. Pravastatin compared to bezafibrate in the treatment of dyslipidemia in insulin-treated patients with type 2 diabetes mellitus.
    Rustemeijer C, Schouten JA, Voerman HJ, Hensgens HE, Donker AJ, Heine RJ.
    Diabetes Metab Res Rev; 2000 Jun 25; 16(2):82-7. PubMed ID: 10751747
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Treating mixed dyslipidemias: why and how.
    Ballantyne CM.
    Clin Cardiol; 2001 Jun 25; 24(7 Suppl):II-6-9. PubMed ID: 11444652
    [Abstract] [Full Text] [Related]

  • 18. Long-term safety of pravastatin-gemfibrozil therapy in mixed hyperlipidemia.
    Iliadis EA, Rosenson RS.
    Clin Cardiol; 1999 Jan 25; 22(1):25-8. PubMed ID: 9929751
    [Abstract] [Full Text] [Related]

  • 19. Effects of gemfibrozil conversion to fenofibrate on lipids in patients on statin therapy.
    Corbelli JC, Bullano MF, Willey VJ, Cziraky MJ, Corbelli ME, Waugh W.
    Am J Cardiol; 2002 Dec 15; 90(12):1388-91. PubMed ID: 12480052
    [No Abstract] [Full Text] [Related]

  • 20. Predictors of change in low-density lipoprotein size during lipid-lowering treatment in type 2 diabetes.
    Wägner AM, Ordóñez-Llanos J, Jorba O, Pérez A.
    Metabolism; 2004 Nov 15; 53(11):1516. PubMed ID: 15558848
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.